cisplatin

Generic: cisplatin

Labeler: fresenius kabi usa, llc
NDC Directory HUMAN PRESCRIPTION DRUG UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE Inactive Finished

Drug Facts

Product Profile

Brand Name cisplatin
Generic Name cisplatin
Labeler fresenius kabi usa, llc
Dosage Form INJECTION, SOLUTION
Routes
INTRAVENOUS
Active Ingredients

cisplatin 1 mg/mL

Manufacturer
Fresenius Kabi USA, LLC

Identifiers & Regulatory

Product NDC 65219-359
Product ID 65219-359_a91e4890-e792-422b-92f3-8eb99c31aeb7
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE
Listing Expiration 2026-12-31
Marketing Start 2023-09-01

Pharmacologic Class

Established (EPC)
platinum-based drug [epc]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 65219359
Hyphenated Format 65219-359

Supplemental Identifiers

RxCUI
309311
UNII
Q20Q21Q62J
NUI
N0000175413 N0000175073

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name cisplatin (source: ndc)
Generic Name cisplatin (source: ndc)
Routes
INTRAVENOUS
source: ndc

Resolved Composition

Strengths
  • 1 mg/mL
source: ndc
Packaging
  • PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Cisplatin Injection 50 mL Carton Panel 50mg/50 ml Rx Cisplatin Injection BP 1 mg/ml KEMOPLAT Single Dose Vial 50 ml PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Cisplatin Injection 50 mL Carton Panel
  • PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Cisplatin Injection 50 mL Vial Label 50mg/50 ml Rx Cisplatin Injection BP 1 mg /ml Kemoplat Single Dose Vial 50 ml PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Cisplatin Injection 50 mL Vial Label
source: label

Packages (0)

No package records.

Ingredients (1)

cisplatin (1 mg/mL)

Linked Drug Pages (1)

Cisplatin ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["INTRAVENOUS"], "spl_id": "a91e4890-e792-422b-92f3-8eb99c31aeb7", "openfda": {"nui": ["N0000175413", "N0000175073"], "unii": ["Q20Q21Q62J"], "rxcui": ["309311"], "spl_set_id": ["851e111b-d7c9-4781-849b-3d036e13ce3f"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [], "brand_name": "Cisplatin", "product_id": "65219-359_a91e4890-e792-422b-92f3-8eb99c31aeb7", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Platinum-based Drug [EPC]", "Platinum-containing Compounds [EXT]"], "product_ndc": "65219-359", "generic_name": "CISPLATIN", "labeler_name": "Fresenius Kabi USA, LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Cisplatin", "active_ingredients": [{"name": "CISPLATIN", "strength": "1 mg/mL"}], "marketing_category": "UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE", "marketing_start_date": "20230901", "listing_expiration_date": "20261231"}